Research progress of immune checkpoint inhibitors associated pneumonia
-
摘要:
免疫检查点抑制剂(ICIs)被广泛应用于多种恶性肿瘤的治疗，但由ICIs诱导的免疫系统过度激活也会导致T细胞对自身抗原进行攻击，临床上出现一系列免疫相关不良事件(IRAEs)。免疫检查点抑制剂相关性肺炎(CIP)是一类少见但有潜在致命危险的免疫相关不良反应，发生在肿瘤免疫治疗任何时间。临床医生应了解CIP的机制及特征，及早识别并正确处理。本文就CIP的流行病学、生物学机制、临床特征、诊断及治疗等进行综述。关键词: 免疫检查点抑制剂; 免疫系统; 免疫检查点抑制剂相关性肺炎; 流行病学; 生物学机制
-
关键词:
- 免疫检查点抑制剂 /
- 免疫系统 /
- 免疫检查点抑制剂相关性肺炎 /
- 流行病学 /
- 生物学机制
Abstract:Immune checkpoint inhibitors (ICIS) are widely used in the treatment of a variety of malignant tumors, but the over activation of the immune system induced by ICIS will also lead to T cells attacking their own antigens, and cause a series of immune related adverse events (IRAEs) in clinic. Immune checkpoint inhibitor associated pneumonia (CIP) is a rare but potentially fatal immune related adverse reaction that occurs at any time of tumor immunotherapy. Clinicians should understand the mechanism and characteristics of CIP, and identify and deal with it correctly as soon as possible. This paper reviewed the epidemiology, biological mechanism, clinical characteristics, diagnosis and treatment of CIP.
-
-
[1] ALSAAB H O, SAU S, ALZHRANI R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome[J]. Front Pharmacol, 2017, 8: 561. doi: 10.3389/fphar.2017.00561
[2] 崔建东, 张羽, 王红治. 免疫检查点抑制剂在非小细胞肺癌治疗中的临床应用[J]. 肿瘤药学, 2019, 9(1): 14-19. doi: 10.3969/j.issn.2095-1264.2019.01.04 [3] FRIEDMAN C F, PROVERBS-SINGH T A, POSTOW M A. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review[J]. JAMA Oncol, 2016, 2(10): 1346-1353. doi: 10.1001/jamaoncol.2016.1051
[4] POZZESSERE C, BOUCHAAB H, JUMEAU R, et al. Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study[J]. ERJ Open Res, 2020, 6(1): 00165-02019.
[5] SURESH K, NAIDOO J, LIN C T, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities[J]. Chest, 2018, 154(6): 1416-1423. doi: 10.1016/j.chest.2018.08.1048
[6] BOUTROS C, TARHINI A, ROUTIER E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J]. Nat Rev Clin Oncol, 2016, 13(8): 473-486. doi: 10.1038/nrclinonc.2016.58
[7] BAXI S, YANG A N, GENNARELLI R L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis[J]. BMJ, 2018, 360: k793.
[8] WANG D Y, SALEM J E, COHEN J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. doi: 10.1001/jamaoncol.2018.3923
[9] NISHINO M, RAMAIYA N H, AWAD M M, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course[J]. Clin Cancer Res, 2016, 22(24): 6051-6060. doi: 10.1158/1078-0432.CCR-16-1320
[10] NISHINO M, HATABU H. Programmed death-1/programmed death ligand-1 inhibitor-related pneumonitis and radiographic patterns[J]. J Clin Oncol, 2017, 35(14): 1628-1629.
[11] NISHINO M, GIOBBIE-HURDER A, HATABU H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2016, 2(12): 1607-1616. doi: 10.1001/jamaoncol.2016.2453
[12] HODI F S, O'DAY S J, MCDERMOTT D F, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8): 711-723. doi: 10.1056/NEJMoa1003466
[13] WOLCHOK J D, NEYNS B, LINETTE G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study[J]. Lancet Oncol, 2010, 11(2): 155-164. doi: 10.1016/S1470-2045(09)70334-1
[14] KUMAR V, CHAUDHARY N, GARG M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy[J]. Front Pharmacol, 2017, 8: 49. doi: 10.3389/fphar.2017.00049
[15] ATCHLEY W T, ALVAREZ C, SAXENA-BEEM S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer[J]. Chest, 2021, 160(2): 731-742. doi: 10.1016/j.chest.2021.02.032
[16] SURESH K, VOONG K R, SHANKAR B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors[J]. J Thorac Oncol, 2018, 13(12): 1930-1939. doi: 10.1016/j.jtho.2018.08.2035
[17] TONE M, IZUMO T, AWANO N, et al. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer[J]. Thorac Cancer, 2019, 10(10): 2006-2012. doi: 10.1111/1759-7714.13187
[18] CHO J Y, KIM J, LEE J S, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer[J]. Lung Cancer, 2018, 125: 150-156. doi: 10.1016/j.lungcan.2018.09.015
[19] NISHINO M, HATABU H, HODI F S, et al. Drug-related pneumonitis in the era of precision cancer therapy[J]. JCO Precis Oncol, 2017, 1: PO. 17. 00026.
[20] SHOHDY K S, ABDEL-RAHMAN O. Risk of pneumonitis with different immune checkpoint inhibitors in NSCLC[J]. Ann Transl Med, 2017, 5(17): 365. doi: 10.21037/atm.2017.06.67
[21] FUJⅡ T, COLEN R R, BILEN M A, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience[J]. Investig New Drugs, 2018, 36(4): 638-646. doi: 10.1007/s10637-017-0534-0
[22] POSTOW M A, SIDLOW R, HELLMANN M D. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. doi: 10.1056/NEJMra1703481
[23] TABCHI S, MESSIER C, BLAIS N. Immune-mediated respiratory adverse events of checkpoint inhibitors[J]. Curr Opin Oncol, 2016, 28(4): 269-277. doi: 10.1097/CCO.0000000000000291
[24] LATCHMAN Y, WOOD C R, CHERNOVA T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol, 2001, 2(3): 261-268. doi: 10.1038/85330
[25] CHUZI S, TAVORA F, CRUZ M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis[J]. Cancer Manag Res, 2017, 9: 207-213. doi: 10.2147/CMAR.S136818
[26] HASSEL J C, HEINZERLING L, ABERLE J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions[J]. Cancer Treat Rev, 2017, 57: 36-49. doi: 10.1016/j.ctrv.2017.05.003
[27] NAIDOO J, WANG X, WOO K M, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7): 709-717. doi: 10.1200/JCO.2016.68.2005
[28] 王汉萍, 郭潇潇, 周佳鑫, 等. 免疫检查点抑制剂相关肺炎的临床诊治建议[J]. 中国肺癌杂志, 2019, 22(10): 621-626. doi: 10.3779/j.issn.1009-3419.2019.10.03 [29] WIDMANN G, NGUYEN V A, PLAICKNER J, et al. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy[J]. Curr Radiol Rep, 2016, 5(11): 59.
[30] DELAUNAY M, CADRANEL J, LUSQUE A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients[J]. Eur Respir J, 2017, 50(2): 1700050. doi: 10.1183/13993003.00050-2017
[31] SUZUKI K, YANAGIHARA T, MATSUMOTO K, et al. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease[J]. Int Immunol, 2020, 32(8): 547-557. doi: 10.1093/intimm/dxaa022
[32] NAKASHIMA K, NAITO T, OMORI S, et al. Organizing pneumonia induced by nivolumab in a patient with metastatic melanoma[J]. J Thorac Oncol, 2016, 11(3): 432-433. doi: 10.1016/j.jtho.2015.10.004
[33] ISHIWATA T, EBATA T, IWASAWA S, et al. Nivolumab-induced acute fibrinous and organizing pneumonia (AFOP)[J]. Intern Med, 2017, 56(17): 2311-2315. doi: 10.2169/internalmedicine.8271-16
[34] BARJAKTAREVIC I Z, QADIR N, SURI A N, et al. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma[J]. Chest, 2013, 143(3): 858-861. doi: 10.1378/chest.12-1467
[35] MATSUKANE R, WATANABE H, MINAMI H, et al. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events[J]. Sci Rep, 2021, 11(1): 1324. doi: 10.1038/s41598-020-79397-6
[36] 王锋, 秦叔逵, 华海清, 等. 免疫检查点抑制剂相关性肺炎的临床特点及分型研究[J]. 临床肿瘤学杂志, 2021, 26(6): 541-549. doi: 10.3969/j.issn.1009-0460.2021.06.011 [37] ZHAI X Y, ZHANG J, TIAN Y R, et al. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients[J]. Cancer Biol Med, 2020, 17(3): 599-611. doi: 10.20892/j.issn.2095-3941.2020.0102
[38] KALISZ K R, RAMAIYA N H, LAUKAMP K R, et al. Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management[J]. Radiographics, 2019, 39(7): 1923-1937. doi: 10.1148/rg.2019190036
[39] 张勇. 肿瘤免疫检查点抑制剂相关肺炎的管理[J]. 中国临床医学, 2020, 27(6): 922-925. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX202006006.htm [40] THOMPSON J A. New NCCN guidelines: recognition and management of immunotherapy-related toxicity[J]. J Natl Compr Canc Netw, 2018, 16(5S): 594-596. doi: 10.6004/jnccn.2018.0047
计量
- 文章访问数:
- HTML全文浏览量:
- PDF下载量:
下载:
苏公网安备 32100302010246号